1. Jørgensen, JT . Clinical application of companion diagnostics. Trends Mol Med. 2015;21:405-407.
Google Scholar | Crossref | Medline2. Jørgensen, JT . Companion and complementary diagnostics: an important treatment decision tool in precision medicine. Expert Rev Mol Diagn. 2020;20:557-559.
Google Scholar | Crossref | Medline3. Jørgensen, JT, Hersom, M. Companion diagnostics-a tool to improve pharmacotherapy. Ann Transl Med. 2016;4:482.
Google Scholar | Crossref | Medline4. TGA . IVD companion diagnostics – guidance on regulatory requirements. Published 2020. https://www.tga.gov.au/sites/default/files/ivd-companion-diagnostics.pdf
Google Scholar5. Beeler, JF . Integrating diagnostic products into the drug development workflow: applications for companion diagnostics. In: Shimasaki, C , ed. Biotechnology Entrepreneurship. Academic Press; 2020:359-370.
Google Scholar6. Gibson, DS, Bustard, MJ, McGeough, CM, et al. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Rev Mol Diagn. 2015;15:219-234.
Google Scholar | Crossref | Medline7. Ptolemy, AS, Rifai, N. What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scand J Clin Lab Invest Suppl. 2010;242:6-14.
Google Scholar | Crossref | Medline8. Strimbu, K, Tavel, JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463-466.
Google Scholar | Crossref | Medline | ISI9. Taylor, CR . Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: “in situ proteomics,” or just a “stain”? Appl Immunohistochem Mol Morphol. 2014;22:555-561.
Google Scholar | Crossref | Medline10. Aspinall, MG, Hamermesh, RG. Realizing the promise of personalized medicine. Harv Bus Rev. 2007;85:108-165.
Google Scholar | Medline | ISI11. Barrera-Saldaña, HA . Origin of personalized medicine in pioneering, passionate, genomic research. Genomics. 2020;112:721-728.
Google Scholar | Crossref | Medline12. Offit, K . Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130:3-14.
Google Scholar | Crossref | Medline | ISI13. Schilsky, RL . Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010;9:363-366.
Google Scholar | Crossref | Medline | ISI14. Schwaederle, M, Zhao, M, Lee, JJ, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33:3817-3825.
Google Scholar | Crossref | Medline | ISI15. FDA . List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Published 2021. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
Google Scholar16. Mpye, KL, Matimba, A, Dzobo, K, Chirikure, S, Wonkam, A, Dandara, C. Disease burden and the role of pharmacogenomics in African populations. Glob Health Epidemiol Genom. 2017;2:e1.
Google Scholar | Crossref | Medline17. Nicolaou, CA, Brown, N. Multi-objective optimization methods in drug design. Drug Discov Today Technol. 2013;10:e427-e435.
Google Scholar | Crossref | Medline18. Nikolcheva, T, Jäger, S, Bush, TA, Vargas, G. Challenges in the development of companion diagnostics for neuropsychiatric disorders. Expert Rev Mol Diagn. 2011;11:829-837.
Google Scholar | Crossref | Medline19. Elliott, P, Cowie, MR, Franke, J, et al. Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology-Cardiovascular round table. Cardiovasc Res. 2021;117:1248-1256.
Google Scholar | Crossref | Medline20. Geem, D, Kugathasan, S. It takes two to make it right: dual biologic and small molecule therapy for treatment-refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1361-1362.
Google Scholar | Crossref | Medline21. Iliodromiti, S, Salje, B, Dewailly, D, et al. Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum Reprod. 2017;32:1710-1715.
Google Scholar | Crossref | Medline22. John, A, Shah, RA, Wong, WB, Schneider, CE, Alexander, M. Value of precision medicine in advanced non-small cell lung cancer: real-world outcomes associated with the use of companion diagnostics. Oncologist. 2020;25:e1743-e1752.
Google Scholar | Crossref | Medline23. Meinert, E, Alturkistani, A, Luo, D, et al. Chapter 25 – current status and future direction of companion diagnostics. In: Jørgensen, JT , ed. Companion and Complementary Diagnostics. Academic Press; 2019;455-472.
Google Scholar | Crossref24. Comment, LA, Ward, AF, Schrock, AB, et al. Evidence-Based development and clinical use of precision oncology therapeutics. Clin Pharmacol Ther. 2020;108:440-443.
Google Scholar | Crossref | Medline25. Papadopoulos, N, Kinzler, KW, Vogelstein, B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol. 2006;24:985-995.
Google Scholar | Crossref | Medline26. FDA . New drug therapy approvals 2019. Published 2020. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019.
Google Scholar27. Gromova, M, Vaggelas, A, Dallmann, G, Seimetz, D. Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomark Insights. 2020;15:1177271920974652.
Google Scholar | SAGE Journals | ISI28. Campbell, MR . Update on molecular companion diagnostics – a future in personalized medicine beyond Sanger sequencing. Expert Rev Mol Diagn. 2020;20:637-644.
Google Scholar | Crossref | Medline29. Poulsen, TBG, Karamehmedovic, A, Aboo, C, et al. Protein array-based companion diagnostics in precision medicine. Expert Rev Mol Diagn. 2020;20:1183-1198.
Google Scholar | Crossref | Medline30. FDA . In vitro companion diagnostic devices guidance for industry and Food and Drug Administration Staff, Published August 2014. https://www.fda.gov/media/81309/download
Google Scholar31. Scheerens, H, Malong, A, Bassett, K, et al. Current status of companion and complementary diagnostics: strategic considerations for development and launch. Clin Transl Sci. 2017;10:84-92.
Google Scholar | Crossref | Medline32. A brief history of Herceptin® and the Her2 cancer gene . Published February 2021. https://www.breastcenter.com/2020/03/04/a-brief-history-of-herceptin-and-the-her2-cancer-gene/
Google Scholar33. Hurvitz, S, McCann, K. Chapter 2 – HER2 testing in the era of changing guidelines. In: Hurvitz, S, McCann, K, eds. Her2-Positive Breast Cancer. Elsevier; 2019;13-39.
Google Scholar34. Khoury, JD, Catenacci, DV. Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med. 2015;139:11-13.
Google Scholar | Crossref | Medline35. Dailey, PJ, Elbeik, T, Holodniy, M. Companion and complementary diagnostics for infectious diseases. Expert Rev Mol Diagn. 2020;20:619-636.
Google Scholar | Crossref | Medline36. Schluckebier, L, Caetano, R, Garay, OU, et al. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20:875.
Google Scholar | Crossref | Medline37. Cree, IA . Progress and potential of RAS mutation detection for diagnostics and companion diagnostics. Expert Rev Mol Diagn. 2016;16:1067-1072.
Google Scholar | Crossref | Medline38. Doostparast Torshizi, A, Wang, K. Next-generation sequencing in drug development: target identification and genetically stratified clinical trials. Drug Discov Today. 2018;23:1776-1783.
Google Scholar | Crossref | Medline39. Mansfield, AS, Park, BH, Mullane, MP. Identification, prioritization, and treatment of mutations identified by next-generation sequencing. Am Soc Clin Oncol Educ Book. 2018;38:873-880.
Google Scholar | Crossref | Medline40. Koelzer, VH, Sirinukunwattana, K, Rittscher, J, Mertz, KD. Precision immunoprofiling by image analysis and artificial intelligence. Virchows Arch. 2019;474:511-522.
Google Scholar | Crossref | Medline41. Shah, P, Kendall, F, Khozin, S, et al. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit Med. 2019;2:69.
Google Scholar | Crossref | Medline42. Washington, P, Park, N, Srivastava, P, et al. Data-driven diagnostics and the potential of mobile artificial intelligence for digital therapeutic phenotyping in computational psychiatry. Biol Psychiatr Cogn Neurosci Neuroimaging. 2020;5(8):759-769.
Google Scholar | Crossref | Medline43. Kaufmann, M, Keppens, M, Blair, ED. A perspective analysis: companion diagnostics: an evolving paradigm in 21st century healthcare. Per Med. 2015;12:389-402.
Google Scholar | Crossref | Medline44. Keeling, P, Clark, J, Finucane, S. Challenges in the clinical implementation of precision medicine companion diagnostics. Expert Rev Mol Diagn. 2020;20:593-599.
Google Scholar | Crossref | Medline45. Lütkemeyer, D, Heese, HS, Wuttke, DA. Overcoming inefficiencies in the development of personalized medicine. Eur J Oper Res. 2021;290:278-296.
Google Scholar | Crossref46. Agarwal, A, Ressler, D, Snyder, G. The current and future state of companion diagnostics. Pharmacogenomics Pers Med. 2015;8:99-110.
Google Scholar | Medline47. Peterson, RE, Kuchenbaecker, K, Walters, RK, et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. Cell. 2019;179:589-603.
Google Scholar | Crossref | Medline48. FDA . FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug, Published March 2017. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor
Google Scholar49. Alyass, A, Turcotte, M, Meyre, D. From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genomics. 2015;8:33.
Google Scholar | Crossref | Medline50. Joyner, MJ, Paneth, N. Seven questions for personalized medicine. JAMA. 2015;314:999-1000.
Google Scholar | Crossref | Medline | ISI51. Parkinson, DR, Johnson, BE, Sledge, GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res. 2012;18:619-624.
Google Scholar | Crossref | Medline52. Reavie, L . Four important considerations for the successful development of an in vitro or companion diagnostic test. Published November 2018. https://www.biopharma-excellence.com/news/2018/11/21/four-important-considerations-for-the-successful-development-of-an-in-vitro-or-companion-diagnostic-test
Google Scholar53. IVDR . The European Parliament and the Council of the European Union: Regulation (EU) 2017/746 of the European Parliament and of the Council on In Vitro Diagnostic Medical Devices and Repealing Directive 98/79/EC and Commission Decision 2010/227/EU. European Union; 2017. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746